Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) --

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations of the Securities Exchange Act of 1934. Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages. The Company's lead product candidate is Omburtamab. According to Y-mAbs, '131I-omburtamab, which is omburtamab radiolabeled with Iodine-131, is currently being studied in several clinical trials including pivotal stage development Study 101 and Study 03-133 for the treatment of pediatric patients who have CNS/LM from NB.”

What Now: Similarly situated shareholders may be eligible to participate in the class action against Y-mAbs. Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case аbout: Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate

According to the complaint, Y-mAbs sought FDA approval of omburtamab through a Biologics License Application first in 2020 and again in 2022, based on a comparison between Study 03-133 performed at Memorial Sloan Kettering Cancer Center (“MSKCC”) and an external cohort comprising data from the Central German Childhood Cancer Registry, or CGCCR, database.

The FDA declined marketing approval of omburtamab in a Refusal to File (RTF) letter dated October 2, 2020, informing Y-mAbs that additional data, including evidence of durable response were necessary to provide the level of evidence needed to support an approval.

Y-mAbs disclosed the existence of the RTF letter in a press release dated October 5, 2020, and in an investor conference call the morning of October 6, 2020, but misrepresented the FDA’s willingness to approve omburtamab for marketing based on the existing clinical trials. In fact, during the class period, Y-mAbs misrepresented to investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, progress was being made that would align with the FDA’s requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies.

To the contrary, the FDA had repeatedly advised the defendants that the FDA was unlikely to grant approval for the marketing of omburtamab based on a comparison between Study 03-133 and CGCCR because of substantial differences in the patient populations, and the absence of tumor response data, and that Study 101 was neither sufficiently advanced nor indicative of efficacy to justify approval. The truth was first disclosed to investors on October 26, 2022, when the FDA published its Briefing Document for an October 28, 2022 Advisory Committee Meeting, and again on October 28, 2022, when the Committee voted 16-0 against recommending approval of omburtamab. On this news, Y-mAbs common shares fell $11.56 per share, to close at $3.61 per share on October 31, 2022.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Y-mAbs Therapeutic, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/



Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

TIN LIÊN QUAN

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs

SAN FRANCISCO, March 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of...

Notice of Filing Securities Class Action Against Global

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

THỦ THUẬT HAY

Hướng dẫn mang một số tính năng đặc biệt trên Pixel 2 lên bất kỳ thiết bị Android nào

Always on Display, Always listening, AR Stickers, Motion Photos và Home screen Layout là những tính năng mới được Google trang bị riêng cho bộ đôi smartphone cao cấp mới ra thời gian gần đây. Tuy nhiên, chúng ta vẫn có

Hướng dẫn cập nhật iOS lên iOS 12 bản chính thức

iOS 12 tập trung vào cải thiện hiệu suất. Tốc độ mở ứng dụng có thể cải thiện tới 70%. Camera mở nhanh hơn đến 70%. Ngoài ra, còn nhiều cải thiện trên hệ thống để các ứng dụng có thể chạy nhanh

Cách đóng tab bị treo khi sử dụng Chorme dễ dàng

Nguyên nhân dẫn đến các tab bị treo có thể là do trang web đó quá nặng dẫn đến đầy RAM, đây cũng là lý do chính mà những máy tính có dung lượng RAM 4GB hoặc nhỏ hơn rất hay gặp. Ngoài ra cũng có nhiều nguyên nhân khác

Mách bạn bí quyết học online hiệu quả tại nhà trong mùa dịch

Hiện tại dịch Covid 19 vẫn còn diễn biến phức tạp, vì vậy chúng ta đang áp dụng phổ biến hình thức dạy và học online. Tuy nhiên, nhiều bạn vẫn chưa biết cách học thế nào cho hiệu quả. Ngay sau đây, sẽ chia sẻ với bạn

Cách ẩn bình luận cá nhân trên Facebook đơn giản chỉ với 5 bước

Facebook hiện đang là một trong số những nền tảng mạng xã hội được ưa chuộng nhất, bạn rất ngại khi mỗi lần muốn bình luận vào một bài viết nào đó nhưng không biết ẩn bình luận thì hãy tham khảo bài viết bên dưới.

ĐÁNH GIÁ NHANH

Đánh giá nhanh BMW R nineT Racer tại Hà Nội

Nhắm tới đối tượng người chơi xe classic và đặc biệt yêu thích dòng café racer, BMW R nineT Racer đã xuất hiện chính hãng tại Việt Nam sẵn sàng đối đầu với Triumph Thruxton R.

Đánh giá pin iPhone 13: Thời gian sử dụng xuất sắc, thời gian sạc còn hạn chế

Khi ra mắt iPhone 13, Apple cho biết pin của nó tốt hơn thế hệ tiền nhiệm. Vậy cụ thể như thế nào? Mời bạn cùng chúng tôi đánh giá pin iPhone 13 để biết thêm chi tiết nhé. iPhone 13 có dung lượng pin bao nhiêu? Để biết